Skip to main content

이대원 교수

Lee, Dae Won

서울대학교 내과 · 의학

연구실 소개

이대원 교수의 연구실은 주로 암 생물학과 정밀의료를 융합한 연구를 수행하고 있습니다. 특히 결장암, 간세포암, 유방암 등에서 종양 미세환경의 면역 조절 메커니즘과 종양 돌연변이 부하(TMB)가 임상적 예후에 미치는 영향을 분석하며, 표적 치료 및 면역요법의 효과를 평가하고 있습니다. 또한, 암 환자의 신경학적 합병증인 뇌막암성전이 등 희귀 암성 질환의 치료 전략 개발에도 기여하고 있습니다. 이 연구들은 임상 적용에 적합한 바이오마커 및 치료 전략을 도출하는 데 초점을 맞추고 있습니다.

종양 미세환경암 예후 마커면역요법 반응종양 돌연변이 부하희귀 암성 합병증

연구 현황

논문 수
118
총 인용 수
2,192
최근 5년 논문
55
주요 분야
의학

연구 성과 추이

표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.

5개년 연도별 논문 게재 수
55총합
2022
2023
2024
2025
2026
5개년 연도별 피인용 수
377총합
20222023202420252026

주요 논문

15
1
논문|인용수 238·2009
Feedback Linearization vs. Adaptive Sliding Mode Control for a Quadrotor Helicopter
이대원, Shankar Sastry, 김현진

This paper presents two types of nonlinear controllers for an autonomous quadrotor helicopter. One type, a feedback linearization controller involves high-order derivative terms and turns out to be quite sensitive to sensor noise as well as modeling uncertainty. The second type involves a new approach to an adaptive sliding mode controller using input augmentation in order to account for the underactuated property of the helicopter, sensor noise, and uncertainty without using control inputs of l

2
논문|인용수 145·2019
Tumor Mutation Burden and Prognosis in Patients with Colorectal Cancer Treated with Adjuvant Fluoropyrimidine and Oxaliplatin
Dae-Won Lee, Sae‐Won Han, Jeong Mo Bae, Hoon Jang, Hyojun Han, Hyoki Kim, Duhee Bang, Seung‐Yong Jeong, Kyu Joo Park, Gyeong Hoon Kang, Tae‐You Kim
SJR Q1Clinical Cancer Research

Abstract Purpose: Recent sequencing studies revealed that a subset of colorectal cancer harbors a significantly higher number of somatic mutations. These hypermutated tumors show distinct clinicopathologic features. However, the prognostic impact of the hypermutated tumors is not clearly established. Experimental Design: We analyzed tumor mutation burden (TMB) from targeted next-generation sequencing data of 40 major genes in 516 patients with colorectal cancer. TMB was defined as total number o

OncologyMedicine
3
논문|인용수 99·2018
Association Between Fusobacterium nucleatum, Pathway Mutation, and Patient Prognosis in Colorectal Cancer
Dae‐Won Lee, Sae‐Won Han, Jun-Kyu Kang, Jeong Mo Bae, Hwang-Phill Kim, Jae‐Kyung Won, Seung‐Yong Jeong, Kyu Joo Park, Gyeong Hoon Kang, Tae‐You Kim
SJR Q1Annals of Surgical Oncology
Molecular BiologyBiochemistry, Genetics and Molecular Biology
4
논문|인용수 82·2014
KRAS Mutation is Associated with Worse Prognosis in Stage III or High-risk Stage II Colon Cancer Patients Treated with Adjuvant FOLFOX
Dae-Won Lee, Kyung Ju Kim, Sae‐Won Han, Hyun Jung Lee, Ye Young Rhee, Jeong Mo Bae, Nam‐Yun Cho, Kyung-Hun Lee, Tae Yong Kim, Do‐Youn Oh, Seock‐Ah Im, Yung‐Jue Bang
SJR Q1Annals of Surgical Oncology
OncologyMedicine
5
논문|인용수 60·2017
Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer
Dae‐Won Lee, Sae‐Won Han, Yongjun Cha, Jeong Mo Bae, Hwang‐Phill Kim, Jaemyun Lyu, Hyojun Han, Hyoki Kim, Hoon Jang, Duhee Bang, Iksoo Huh, Taesung Park
SJR Q1CancerOA

BACKGROUND: Colorectal cancer (CRC) develops through the alteration of several critical pathways. This study was aimed at evaluating the influence of critical pathways on survival outcomes for patients with CRC. METHODS: Targeted next-generation sequencing of 40 genes included in the 5 critical pathways of CRC (WNT, P53, RTK-RAS, phosphatidylinositol-4,5-bisphosphate 3-kinase [PI3K], and transforming growth factor β [TGF-β]) was performed for 516 patients with stage III or high-risk stage II CRC

OncologyMedicine
6
리뷰|인용수 41·2016
Molecular Targeted Therapies for the Treatment of Leptomeningeal Carcinomatosis: Current Evidence and Future Directions
Dae‐Won Lee, Kyung-Hun Lee, Jin Ho Kim, Bhumsuk Keam
SJR Q1International Journal of Molecular SciencesOA

Leptomeningeal carcinomatosis (LMC) is the multifocal seeding of cerebrospinal fluid and leptomeninges by malignant cells. The incidence of LMC is approximately 5% in patients with malignant tumors overall and the rate is increasing due to increasing survival time of cancer patients. Eradication of the disease is not yet possible, so the treatment goals of LMC are to improve neurologic symptoms and to prolong survival. A standard treatment for LMC has not been established due to low incidences o

Pulmonary and Respiratory MedicineMedicine
7
논문|인용수 39·2020
Phase II Study of Avelumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib
Dae-Won Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Yoon Jun Kim, Jung‐Hwan Yoon, Tae‐Yong Kim, Sae‐Won Han, Do‐Youn Oh, Seock‐Ah Im, Tae‐You Kim, Young-Eun Lee
SJR Q1Clinical Cancer ResearchOA

Abstract Purpose: This study investigated the efficacy and safety of avelumab, an anti-programmed death ligand 1 (PD-L1) antibody, in patients with advanced hepatocellular carcinoma previously treated with sorafenib (NCT03389126). Patients and Methods: This is a single-arm, single center, phase II trial. Patients with Child-Pugh A score who had at least one measurable lesion were enrolled. Intravenous avelumab 10 mg/kg every 2 weeks was given until disease progression or unacceptable toxicity. T

HepatologyMedicine
8
논문|인용수 29·2019
Immune recurrence score using 7 immunoregulatory protein expressions can predict recurrence in stage I–III breast cancer patients
Dae‐Won Lee, Han Suk Ryu, Min‐Sun Jin, Kyung-Hun Lee, Koung Jin Suh, Jeonghwan Youk, Jung Youn Kim, Ahrum Min, Han‐Byoel Lee, Hyeong‐Gon Moon, Tae‐Yong Kim, Sae‐Won Han
SJR Q1British Journal of CancerOA

BACKGROUND: Immune cells in the tumour microenvironment play an essential role in tumorigenesis. This study aimed to evaluate the immunoregulatory protein expression of breast cancer and reveal their prognostic role. METHODS: Expression of 10 immune markers (PD-1/PD-L1/PD-L2/IDO/TIM-3/OX40/OX40L/B7-H2/ B7-H3/B7-H4) with known/possible clinical relevance was identified in stromal tumour-infiltrating lymphocytes or tumour tissue of stage I-III breast cancer patients. RESULTS: A total of 392 patien

OncologyMedicine
9
논문|인용수 25·2020
Body mass index and body weight change during adjuvant chemotherapy in colon cancer patients: results from the AVANT trial
Dae‐Won Lee, Sooyoung Cho, Aesun Shin, Sae‐Won Han, Tae‐You Kim
SJR Q1Scientific ReportsOA

While obesity increases colorectal cancer incidence, there are inconsistent results in the prognostic role of obesity or body weight change on survival. This study investigated the prognostic impact of body weight and weight change in stage III or high risk stage II colon cancer patients. We used data from patients enrolled in the phase III AVANT trial. The AVANT trial investigated the efficacy of adding bevacizumab to standard adjuvant chemotherapy (FOFOX or XELOX). Weight change during the fir

OncologyMedicine
10
리뷰|인용수 24·2016
TTP as a surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: meta-analysis of randomised controlled trials
Dae-Won Lee, Myoung‐jin Jang, Kyung-Hun Lee, Eun Ju Cho, Jeong‐Hoon Lee, Su Jong Yu, Yoon Jun Kim, Jung‐Hwan Yoon, Tae‐Yong Kim, Sae‐Won Han, Do‐Youn Oh, Seock‐Ah Im
SJR Q1British Journal of CancerOA

Our study results suggest that TTP could be used as a surrogate marker for OS in the clinical trials of advanced HCC. However, the results suggest modest correlation between treatment effects on TTP and OS.

HepatologyMedicine
11
논문|인용수 20·2015
Different prognostic effect of CpG island methylation according to sex in colorectal cancer patients treated with adjuvant FOLFOX
Dae‐Won Lee, Sae‐Won Han, Yongjun Cha, Ye Young Rhee, Jeong Mo Bae, Nam‐Yun Cho, Kyung-Hun Lee, Tae Yong Kim, Do‐Youn Oh, Seock‐Ah Im, Yung‐Jue Bang, Seung‐Yong Jeong
SJR Q1Clinical EpigeneticsOA

BACKGROUND: Profound methylation of CpG islands constitutes a distinct molecular subtype of colorectal cancer (CRC). The frequencies of methylation in CRC vary according to clinico-pathological characteristics including sex. However, interaction between these characteristics and prognostic influence of methylation status has not been clearly defined. We have investigated the prognostic role of promoter methylation using eight CpG island methylator phenotype (CIMP) markers in 497 stage II or III

Molecular BiologyBiochemistry, Genetics and Molecular Biology
12
논문|인용수 14·2023
Circulating Tumor DNA Dynamics and Treatment Outcome of Regorafenib in Metastatic Colorectal Cancer
Dae‐Won Lee, Yoojoo Lim, Hwang‐Phill Kim, Su Yeon Kim, Hanseong Roh, Jun‐Kyu Kang, Kyung‐Hun Lee, Min Jung Kim, Seung‐Bum Ryoo, Ji Won Park, Seung‐Yong Jeong, Kyu Joo Park
SJR Q1Cancer Research and TreatmentOA

PURPOSE: Circulating tumor DNA (ctDNA) is emerging as a valuable non-invasive tool to identify tumor heterogeneity and tumor burden. This study investigated ctDNA dynamics in metastatic colorectal cancer patients treated with regorafenib. Materials and Methods: In this prospective biomarker study, plasma cell-free DNA (cfDNA) samples obtained at baseline, at the first response evaluation after 2 cycles of treatment, and at the time of progressive disease were sequenced using a targeted next-gene

Cancer ResearchBiochemistry, Genetics and Molecular Biology
13
논문|인용수 12·2015
Prognostic influence of body mass index and body weight gain during adjuvant FOLFOX chemotherapy in Korean colorectal cancer patients
Dae‐Won Lee, Sae‐Won Han, Yongjun Cha, Kyung-Hun Lee, Tae‐Yong Kim, Do‐Youn Oh, Seock‐Ah Im, Yung‐Jue Bang, Ji Won Park, Seung‐Bum Ryoo, Seung‐Yong Jeong, Gyeong Hoon Kang
SJR Q2BMC CancerOA

BACKGROUND: Asian population has different body mass index (BMI) profile compared to Caucasian population. However, the effect of obesity and body weight gain in Asian colorectal cancer patients treated with adjuvant chemotherapy has not been studied thus far. METHODS: We have analyzed the association between disease-free survival (DFS) and obesity/body weight change during treatment in Korean stage III or high-risk stage II colorectal cancer patients treated with adjuvant 5-fluorouracil/ leucov

OncologyMedicine
14
논문|인용수 11·2022
Prognostic role of tumor subtype and germline BRCA mutation in advanced breast cancer patients treated with palbociclib plus endocrine therapy
Song Yi Park, Koung Jin Suh, Dae‐Won Lee, Han Suk Ryu, Miso Kim, Se Hyun Kim, Kyung-Hun Lee, Tae‐Yong Kim, Jee Hyun Kim, In Ae Park, Seock‐Ah Im
SJR Q1Breast Cancer Research and Treatment
Pulmonary and Respiratory MedicineMedicine
15
논문|인용수 10·2017
CA19-9 or CEA Decline after the First Cycle of Treatment Predicts Survival in Advanced Biliary Tract Cancer Patients Treated with S-1 and Cisplatin Chemotherapy
Dae‐Won Lee, Seock‐Ah Im, Yu Jung Kim, Yaewon Yang, Jiyoung Rhee, Im Il Na, Kyung-Hun Lee, Tae‐Yong Kim, Sae‐Won Han, In Sil Choi, Do‐Youn Oh, Jee Hyun Kim
SJR Q1Cancer Research and TreatmentOA

Tumor marker decline was associated with improved survival in biliary tract cancer. Measuring tumor marker after the first cycle of chemotherapy can be used as an early assessment of treatment outcome.

SurgeryMedicine

대표 연구 분야

OncologyPulmonary and Respiratory MedicineCancer ResearchMolecular BiologyHepatologySurgery

이대원 교수의 연구를 Nubint에서 더 깊이 살펴보세요

이 연구실의 논문을 앱에서 열어 AI와 함께 읽고, 핵심을 요약하고, 내 글에 인용하세요.